How to invest in 2020s scary markets

In Aug. Later this month, on Nov. Although investors have endured a couple of short-lived rough patches, it’s been an exceptionally strong year for the stock market. If I were a betting man, I’d count on positive reviews all around. Aimmune’s lead drug is Palforzia, an oral drug that’s designed to lessen the symptoms associated with peanut allergy in children and teens. The company is also developing a second location that’ll open next year in Santa Ana, Calif.

Trade uncertainty

It might be hard to believe, but in just seven weeks, we’ll be saying our goodbyes to Although investors have endured a couple of short-lived rough patches, it’s been an exceptionally strong year for the stock market. How good are these returns? Just because the calendar is about to change over to a new year doesn’t mean this optimism can’t carry invdst. If you’re mzrkets for a number of intriguing investment ideas for next year, consider these 20 stocks as possible candidates to double your money in

Big gains could be just a click of the buy button away.

This story is part of the Weekend Brief edition of the Evening Brief newsletter. Stocks may be at record highs as the year winds down, but Wall Street has already started issuing warnings about a host of threats to the markets in Deutsche Bank’s chief economist, Torsten Slok, sent out a list to clients on Friday of 20 risks to the economy and markets next year. CNBC was granted permission to publish the full list. Top on the list of concerns is the «continued increase in wealth inequality,» which is an issue front and center in the current presidential election cycle. Democratic presidential candidates Elizabeth Warren and Bernie Sanders have called for additional taxes on the richest Americans to narrow the wealth gap. Some on Wall Street claimed Warren’s ascent in the presidential pool is set to become the market’s new «wall of worry.

More in Investments

It might be hard to believe, but in just seven weeks, we’ll be saying our goodbyes to Although investors have endured a couple of short-lived rough patches, it’s been an exceptionally strong year for the stock market.

How good are these returns? Just because the calendar is about to change over to a new year doesn’t mean this optimism can’t carry.

If you’re looking for a number of intriguing investment ideas for next year, consider these 20 stocks as possible candidates to double ni money in Yes, cannabis real estate investment trusts REIT are a real thing, and they can be quite lucrative!

After beginning with 11 medical marijuana-growing and processing properties in its portfolio, it now owns 38 properties in 13 states that span 2. The beauty of Innovative industrial Properties’ business model is that it creates highly predictable cash flow. The company’s weighted-average remaining lease term is As long as marijuana remains illicit at the federal level in the U.

That makes Innovative Industrial’s acquisition-and-lease model a veritable green rush gold mine for Like csary brand-name social media sites, Pinterest has seen exceptionally strong user growth. Monthly active user MAU count lnvest to million by the end of September, up 71 million from the prior-year period. Even though ad-based revenue is minimal in foreign markets, it nevertheless demonstrates that Pinterest has global appeal. With Mrkets forecast to push into recurring profitability next year, a doubling of its stock is certainly not out of the question.

Suffice it to say that could be a banner year for this midcap biotech stock. With interest rates and mortgage rates on the rise throughout much ofit looked as if the fun had come to an end for a hot housing market.

But following a trio of Federal Reserve rate cuts and a big drop in Treasury yields, the housing industry is hotter than it’s been in more than a year. Unlike some of the companies you’ll see on this list, profitability isn’t a near-term priority for Redfin. Rather, scaling its tech-driven platform and taking real estate service market share are its primary goals. One way Redfin is doing this is by undercutting traditional real estate agents with its salaried agents.

More so, Redfin is looking to infiltrate the high-margin servicing business to make the buying and selling jnvest less of a hassle. Whereas most of the tech world focuses on bigger names with broader brand recognition, Howw Group’s mobile portfolio of apps, which includes MeetMe, Lovoo, Skout, Tagged, and Growl, has done an admirable job of growing the business.

More specifically, the company’s laser focus on bolstering its video business is really paying dividends. This multiple, and stock, could both easily double and still have room to run.

If this combination therapy dazzles, the duo could snag an even greater share of the RCC market, further boosting Cabometyx’s case as a blockbuster drug.

Investors should also know that Exelixis offers a rare value proposition in the highly competitive and often money-losing biotech space. With patent cliffs remaining challenging for Big Pharma, Exelixis, in addition to potentially notching a win with CheckMate 9ER, might find itself as a buyout candidate in Since Brazil remains largely underbanked, there’s a long-tail opportunity for StoneCo to make its mark 22020s small-and-medium-sized businesses in the country.

StoneCo is also investing heavily into its software subscription model. Although legalizing marijuana across the U. The company’s SuperStore in Las Vegas, Nevada, just west of the Strip, spanssquare feet and will feature a pizzeria, coffee shop, events center, and consumer-facing processing site. Atsquare feet, it’s the largest dispensary in the U.

The company is also developing a second location that’ll open next year in Santa Ana, Calif. Aside from its sheer size and selection, Planet 13’s transparency and technology stand. It could have its investors seeing green in Precious-metal mining isn’t exactly known as a high-growth industry. Treasury inevstFirst Majestic was making waves. Between incorporating the low-cost San Dimas into its portfolio, and looking at ways to bolster its existing assets e.

Historically, the gold-to-silver ratio has hovered around 65, but is currently at closer to This would suggest silver has the potential to outperform gold in the intermediate-term; and no mining company has greater exposure to silver as a percentage of total revenue than First Majestic Silver.

Given that Trupanion is a provider of lifelong insurance policies for cats and dogs. Like any insurance company, Trupanion is built for long-term profitability. Most insurers offer predictable cash flow and have exceptional pricing power, which is a necessity if they’re to cover claims. But Trupanion is going where few insurers have gone. Trupanion is currently unprofitable, but it appears close yow turning the corner to profitability. If the company continues to find success with referrals, it’s very possible it could surprise in the earnings column next year.

What do you get when you combine some of the hottest tech trends into one company? Being able to operate within the confines of traditional enterprise networks, or being tasked with securing cloud networks, Ping offers an assortment of products that should be able to meet the needs of small, medium, and large-scale businesses. Not surprisingly, it should be capable of double-digit sales growth in the near-term, like its peers. This demonstrates the potential of focused individual security, and makes it all the more likely that Ping How to invest in 2020s scary markets could be quickly scooped up by a larger rival.

Livongo is a developer of solutions that helps people change their health habits. By supplying testing kits that connect to smartphones, and utilizing data science, Livongo works to change the go of diabetics, and can also be used to assist patients with hypertension.

Given that over 30 million people have diabetes most being type 2 diabeticsand a number of these folks could use some serious help managing their symptoms, Imvest Health’s products are exactly the disruptor needed in this space. According to the company’s second-quarter results, the number of clients in Livongo’s ecosystem nearly doubled on a year-over-year basis towhile the number of enrolled diabetes members did more than double toMore importantly, Livongo’s triple-digit sales growth rate cannot be overlooked.

While profits are highly unlikely ina year of market-topping revenue growth is very possible. Lovesac, the home furnishings company that sells beanbag chairs, sectional couches, and a host of other in-home decorations, has struggled in amid trade-war concerns. It’s been hit hard by higher tariff costs, and that’s clearly brought investor worry to the forefront.

However, a quick look at Lovesac’s second-quarter operating results should relieve most worries. What’s more, these price hikes don’t appear to be adversely impacting the company’s fast-growing and niche furnishings business. Vascepa, a purified fish 2020 derivative, was approved by the FDA all the way back in to treat patients with severe hypertriglyceridemia SHTG.

Rather, it’s a supplemental new drug application stemming from a five-year Harvard study in 8, people with milder but still high triglyceride levels. In other words, if Vascepa were to be approved for an expanded label indication to reduce the risk of major adverse cardiovascular events, its potential pool of patients could grow tenfold, as would its sales potential.

Later this month, on Nov. If I were a betting man, I’d count on positive reviews all. In Aug. CalAmp, which provides software and subscription-based services, as well as cloud platforms that support a connected economy, has been hurt in recent quarters by the trade war with China, as well as sales weakness in its Telematics segment that’s been tied to a few core customers.

Also, a number of customers blamed for its sales slowdown in Telematics e. As Telematics mzrkets picks back up, the company has seen record sales from its software subscription segment. In short, the CalAmp growth story is just getting started, and could feature some very favorable year-on-year comparisons.

Aimmune’s lead drug is Palforzia, an oral drug that’s designed to lessen the symptoms associated with peanut allergy in children and teens.

Now, here’s the great news: Palforzia looked like a star in late-stage clinical trials. Patients aged 4 to 17 were administered increasingly larger doses of peanut protein during the study, and Even though the FDA isn’t required to follow the vote of its panel of experts, it does so more often than not.

With other treatments in development for egg and walnut allergies, Aimmune looks well on its way to carving its own niche in the biotech space, and potentially doubling its stock in Midstream is the unsung hero of the energy infrastructure space.

While drillers retrieve fossil fuels and refiners process them, it’s midstream providers that are the essential middlemen providing transmission, storage, and a host of other services that ensure these products make it to refineries for processing. Including this payout, Antero Midstream could very well double next year. Marijuana stocks throughout Canada have suffered through sccary issues since day one of adult-use legalization more than marmets year ago.

But one ancillary niche that should be immune to these struggles is extraction services. These are all used in the creation of high-margin derivatives, such as edibles and infused beverages, which were just legalized in Canada on Oct. What’s more, extraction providers like MediPharm often secure contracts ranging from to months, leading to highly predictable cash flow. However, things could change in a big way in For starters, Stitch Fix is a potential retail disruptor that can capitalize on consumers in two ways.

First, there’s the subscription side of the business that includes a stylist who picks outfits and accessories out for customers, who then to decide to keep buy or return these items. The company believes this dual-growth approach will play a key role in revenue growth reacceleration.

Stitch Fix is also planning to expand its offerings to men and children, and would be expected to bolster advertising ivest these new lines roll.

The company pointed out in its most recent quarter that fiscal first-quarter sales guidance is weaker because it lifted its foot off the gas pedal with regard to advertising. That’s an easy fix that should have Stitch Fix mending its weakness pretty quickly in Sometimes, it 2020z requires Wall Street and investors to readjust their outlook. But a renaissance of sorts may be on the horizon. You see, Teva lost more than half of its value in after 44 U. If these opioid suits are resolved, it’s not crazy to think Teva regains pretty much all of the ground it lost when they were announced.

Teva has the potential to really change some opinions inand that could lead to a doubling in its share price. While it’s possible that many, or only a small number, of these 20 companies doubles next year, the important thing for investors to remember is that great ideas often take time to develop. The grandiose secret to marketw creation isn’t going to be found by day-trading or trying to time the market.

It can be fun to predict next year’s top performers and potentially find yourself a proverbial gold mine, but don’t take your eyes off the horizon, which is where the xcary money is being .

Top 5G Stocks to Invest In 2020 — Top 5G Stocks from Emerging Markets + More

1. Innovative Industrial Properties

With Pinterest forecast to push into recurring profitability next year, a doubling of its stock is certainly not out of the question. Between incorporating the low-cost San Dimas into its magkets, and looking at ways to bolster its existing assets e. This multiple, and stock, could both easily double and still have room to run. Inat the pinnacle of post-Brexit panic, we saw government bond yields across the world submerged in negative invedt. One way Redfin is doing this is by undercutting traditional real estate agents with its salaried agents. Eventually we reach the scary bit — when a bond bear market really starts invesy bite. There was a lot of talk of recession. With other treatments in development for egg and walnut allergies, Aimmune looks well on its way to carving its own niche in the how to invest in 2020s scary markets space, and potentially doubling its stock in Treasury yieldsFirst Majestic was making waves.